美沙拉嗪联合结肠炎Ⅰ号治疗31例溃疡性结肠炎患者的临床疗效及对炎症因子的影响

Efficacy of Mesalazine Combined with Colitis Ⅰ in the Treatment of 31 cases of Ulcerative Colitis and Its Influence on Inflammatory Factors

目的观察美沙拉嗪联合结肠炎I号治疗溃疡性结肠炎(ulcerative coltis,UC)的临床疗效及对炎症因子的影响。方法选取2017年6月—2019年9月期间徐州市中医院收治的62例UC患者。采用随机数字表法随机分为对照组和观察组,每组各31例。对照组予以美沙拉嗪治疗,观察组在对照组的治疗基础上加用结肠炎Ⅰ号进行治疗,两组患者均治疗2个月。治疗后,观察比较两组患者临床疗效,治疗前后肠镜检查评分、疾病活动指数(Disease activity index,DAI)、临床症状改善情况以及炎性因子的变化情况。结果治疗后,观察组总有效率90.32%(28/31)高于对照组61.29%(19/31),两组比较,差异有统计学意义(P<0.05)。治疗后,两组患者Baron内镜评分和DAI均明显低于治疗前,差异有统计学意义(P<0.05);且观察组两项指标均明显低于对照组,两组比较,差异有统计学意义(P<0.05)。治疗后,两组患者腹胀、腹泻、腹痛、恶心、脓血便评分均明显低于治疗前,差异有统计学意义(P<0.05);且观察组腹胀、腹泻、腹痛、恶心、脓血便评分均明显低于对照组,两组比较,差异有统计学意义(P<0.05)。治疗后,两组患者血清CRP、IL-6、TNF-α、PCT水平均明显低于治疗前,差异有统计学意义(P<0.05);且观察组血清CRP、IL-6、TNF-α、PCT水平均明显低于对照组,两组比较,差异有统计学意义(P<0.05)。结论美沙拉嗪联合结肠炎Ⅰ号治疗UC临床疗效显著,能有效降低Baron内镜评分和DAI指数,改善临床症状,降低炎症因子水平,有利于UC患者恢复,值得临床推广应用。

Objective To observe the clinical efficacy of mesalazine combined with colitis I in the treatment of ulcerative coltis(UC)and its influence on inflammatory factors.Methods A total of 62 UC patients admitted to Xuzhou Hospital of Traditional Chinese Medicine from June 2017 to September 2019 were selected.Using random number table method,they were randomly divided into control group and observation group,with 31 cases in each group.The control group was treated with mesalazine,and the observation group was treated with colitis No.I on the basis treatment of the control group.Patients in both groups were treated for 2 months.After treatment,the efficacy of the two groups,colonoscopy score,disease activity(DAI)index,improvement of clinical symptoms and changes in inflammatory factors before and after treatment were observed and compared.Results After treatment,the total effective rate of the observation group was 90.32%(28/31)higher than that of the control group 61.29%(19/31),the difference between the two groups was statistically significant(P<0.05).After treatment,the Baron endoscopy score and DAI index of the two groups of patients were significantly lower than before treatment,and the difference was statistically significant(P<0.05),and the two indexes of the observation group were significantly lower than those of the control group.There was a significance difference between the two groups(P<0.05).After treatment,the scores of abdominal distension,diarrhea,abdominal pain,nausea,and pus and blood in the two groups were significantly lower than those before treatment,and the difference was statistically significant(P<0.05).And the observation group had abdominal distension,diarrhea,abdominal pain,nausea,and pus and blood in the stool.Both were significantly lower than the control group,and the difference between the two groups was statistically significant(P<0.05).After treatment,the levels of serum CRP,IL-6,TNF-α,and PCT of the two groups of patients were significantly lower than those before treatment,and the difference was statistically significant(P<0.05);and the levels of serum CRP,IL-6,TNF-αand PCT of the observation group were significantly lower than those of the control group,and the difference between the two groups was statistically significant(P<0.05).Conclusion Mesalazine combined with colitis No.I has a significant effect on the treatment of UC.It can effectively reduce the Baron endoscopy score and DAI index,improve clinical symptoms,and reduce the level of inflammatory factors.It is beneficial to the recovery of UC patients and is worthy of clinical application.